Braxia Scientific Update
MWN-AI** Summary
Braxia Scientific Corp. (CSE: BRAX) has recently provided a significant update on its operational status and financial challenges following a cease trade order from the Ontario Securities Commission (OSC). This order, issued on August 2, 2024, was due to the company's failure to file essential financial documents, including audited annual statements and management discussion for the period ending March 31, 2024. The company attributes this lapse to a change in senior management, particularly the CFO, along with financial constraints that hindered its ability to engage auditors for the necessary filings.
In response to the cease trade order, Braxia's shares were suspended from trading on the Canadian Securities Exchange (CSE) on August 6, 2024. Failure to resolve this situation within 90 days could lead to an automatic delisting, a fate that appears imminent given the company's current financial situation. As of this update, Braxia has not been able to fulfill the filing requirements, and the potential delisting from the CSE looms due to the lack of sufficient resources.
On a more positive note, the company completed the previously announced transaction with Kris Kratiuk on November 22, 2024, where it sold the majority of its assets, including those of its subsidiary, the Canadian Rapid Treatment Center of Excellence. However, this sale has left Braxia with minimal cash reserves and a significant working capital deficiency of over $1.8 million, lacking the means to conduct meaningful operations moving forward.
With only the intellectual property related to its KetaMD platform remaining, Braxia plans to wind down its operations entirely after addressing any employee obligations, with no plans to pursue further business ventures at this time.
MWN-AI** Analysis
Braxia Scientific Corp. has recently communicated critical developments that investors should closely analyze. The company is grappling with a significant regulatory setback, having been issued a failure-to-file cease trade order (FFCTO) by the Ontario Securities Commission due to unfiled audited annual financial statements. This reflects broader governance and liquidity issues as the company struggled with a management overhaul and financial constraints, insufficient to engage auditors for compliance.
As a result of the FFCTO, Braxia's common shares have been suspended from trading on the Canadian Securities Exchange (CSE), with an imminent delisting on the horizon. The regulatory halt raises red flags about the viability of the company moving forward. Given the current financial standing, marked by a substantial working capital deficiency exceeding $1.8 million, investors must proceed with caution.
The recent completion of the asset sale involving its subsidiary, the Canadian Rapid Treatment Center of Excellence, further underscores the company's diminished operational capacity. With the disposal of its core business assets, Braxia is left with limited cash reserves and only the KetaMD platform's intellectual property, for which the management has not provided clear timelines or value expectations from a potential sale.
Given these circumstances, investors are advised to approach Braxia Scientific with skepticism. The likelihood of recovering investment capital remains low, given the company’s winding down of operations and lack of plans for future business endeavors. Monitoring any announcements regarding the disposition of remaining assets or settlement plans for liabilities is crucial; however, overall, the situation appears bleak, and investing in Braxia Scientific carries substantial risk.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Toronto, Ontario--(Newsfile Corp. - February 19, 2025) - Braxia Scientific Corp. (CSE: BRAX) (OTC Pink: BRAXF) (FSE: 4960) ("Braxia Scientific", or the "Company"), provides an update on various matters:
Status of Failure to File Cease Trade Order/CSE Listing
On August 6, 2024, the Company announced that the Ontario Securities Commission (the "OSC") issued a failure-to-file cease trade order (the "FFCTO") to the Corporation on August 2, 2024 , due the Company's failure to file its audited annual financial statements and management discussion & analysis for the financial year ended March 31, 2024, and the CEO and CFO certificates, all as required by National Instrument 51-102 - Continuous Disclosure Obligations and National Instrument 52-109 - Certification of Disclosure in Issuers' Annual and Interim Filings (collectively, the "Documents"). The Documents were required to be filed by July 29, 2024 (the "Filing Deadline").
The Company was not in a position to file the Documents by the Filing Deadline. As previously disclosed, the delay in the preparation and filing of the Documents was due to a change in the Company's CFO and the departure of other senior management. The Company also faced financial constraints which made it unable to engage its auditors to complete the filing.
In addition, as a result of the FFCTO, on August 6, 2024, the Common Shares of the Company were suspended from trading on the Canadian Securities Exchange ("CSE" or "the Exchange"). The suspension is considered a Regulatory Halt as defined in National Instrument 23-101 Trading Rules. The CSE advised that if the Company failed to be reinstated within 90 days of the suspension, the shares would be delisted automatically without notice. The CSE has not delisted the shares as of today's date.
Given the current financial position of the Company outlined below, it is not in a position to complete the filings and anticipates that the securities will be imminently delisted from the CSE.
Completion of Kratiuk Transaction
On October 10, 2024, the Company announced that at the Annual General and Special Meeting of Shareholders held on October 9, 2024, shareholders approved the sale of all or substantially all of the Company's assets in connection with the Company's proposed transaction with Kris Kratiuk, and in particular sale of the assets of the Canadian Rapid Treatment Center of Excellence Inc., the Company's wholly-owned subsidiary and clinic operator. The details of the transactions were as described in the circular for the meeting.
The Transaction was completed on November 22, 2024. The sale does not leave the Company with sufficient resources to continue any meaningful operations. It has minimal cash assets and a significant working capital deficiency in excess of $1,800,000.
KetaMD Platform
The only remaining asset of the Company is the intellectual property related to the KetaMD platform. The Company will make efforts to realize value for these assets. There is no timeline for any such transaction or any guidance on any amount be obtained. In any event, it is unlikely that any meaningful amount will be garnered to satisfy existing liabilities or for a distribution to shareholders.
Wind-up of Operations
As a result, the Company will wind down operations after dealing with any remaining staff obligations. The Company has no plans to continue or pursue any further business at this time.
FOR FURTHER INFORMATION PLEASE CONTACT:
Braxia Scientific Corp.
Tel: 416-762-2138
Email: info@braxiascientific.com
Website: www.braxiascientific.com
The CSE has not reviewed and does not accept responsibility for the accuracy or adequacy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/241555
FAQ**
How does the financial situation of Braxia Scientific Corp (CSE: BRAX) impact the future of similar companies in Toronto's healthcare sector, especially those focused on mental health treatments?
What implications does the failure-to-file cease trade order (FFCTO) of Braxia Scientific Corp (BRAXF) have for investor confidence in Toronto's publicly traded companies?
In light of Braxia Scientific Corp's wind-up of operations, what trends can we expect in Toronto regarding M&A activity in the biotech and cannabis sectors moving forward?
How might the ongoing challenges faced by Braxia Scientific Corp (BRAXF) influence regulatory scrutiny and compliance requirements for other companies listed on the Canadian Securities Exchange?
**MWN-AI FAQ is based on asking OpenAI questions about Braxia Scientific Corp (OTC: BRAXF).
NASDAQ: BRAXF
BRAXF Trading
-99.44% G/L:
$0.0001 Last:
193,510 Volume:
$0.0001 Open:
